(Q40887499)

24 September 2017

1 reference

title

Bronchogenic carcinoma: immunologic aspects (English)

1 reference

24 September 2017

R J Pisani

1

1 reference

24 September 2017

language of work or name

English

0 references

publication date

1 April 1993

1 reference

24 September 2017

1 reference

24 September 2017

volume

68

1 reference

24 September 2017

issue

4

1 reference

24 September 2017

page(s)

386-392

1 reference

Possible immune factors in spontaneous regression of bronchogenic carcinoma. Ten year survival in a patient treated with minimal (1,200 r) radiation alone

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960137-2

Postoperative empyema improves survival in lung cancer. Documentation and analysis of a natural experiment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960137-2

The immune response at the tumor site in lung carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960137-2

Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960137-2

Prospects for the Management of Non-Small-Cell Carcinoma of the Lung with Monoclonal Antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960137-2

Monoclonal antibodies in lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960137-2

Immunoglobulin content in the bronchial washings of patients with benign and malignant pulmonary disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960137-2

Reactive antibodies in the bronchial washings of lung cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960137-2

Phagocytic activity of alveolar macrophages in patients with bronchogenic carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960137-2

Human bronchoalveolar macrophage cytotoxicity for cultured human lung-tumour cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960137-2

Defective cytostatic activity of pulmonary alveolar macrophages in primary lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960137-2

Natural killer cell activity in lung cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960137-2

Lung natural killer and interleukin-2 activity in lung cancer. A pulmonary compartment of augmented natural killer activity occurs in patients with bronchogenic carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960137-2

Lymphokine-activated killer (LAK) cell activity in tumor-infiltrating lymphocytes from non-small cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960137-2

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960137-2

Cytotoxic cell function in bronchogenic carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960137-2

Properties of recombinant interleukin 2-cultured tumor-infiltrating lymphocytes in human lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960137-2

Lymphokine-activated killer cell activity in lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960137-2

Characterization and Purification of an Immunosuppressive Factor Produced by a Small Cell Lung Cancer Cell Line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960137-2

In vitro monocyte maturation in squamous-cell carcinoma of the lung: Influence of humoral factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960137-2

Role of tumor-infiltrating lymphocytes in the host defense mechanism against lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960137-2

Sensitive and specific monoclonal antibody recognition of human lung cancer antigen on preserved sputum cells: a new approach to early lung cancer detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960137-2

Measurement of carcinoembryonic antigen in patients with bronchogenic carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960137-2

Carcinoembryonic Antigen: Its Role as a Marker in the Management of Cancer. A National Institutes of Health Consensus Development Conference

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960137-2

A prospective pilot study evaluating the effectiveness of secretory IgA measurements in bronchoalveolar lavage to detect non-small cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960137-2

131I and 111In-labelled monoclonal antibody imaging of primary lung carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960137-2

Impaired immunologic reactivity and recurrence following cancer surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960137-2

Immunocompetence in lung cancer. Relationship to extent of tumor burden and histologic type

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960137-2

Soluble interleukin 2 receptor in lung cancer. An indirect marker of tumor activity?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960137-2

Immune reactivity in bronchogenic carcinoma and its relation to 5-year survival rate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960137-2

Lysis of autologous tumor cells by blood lymphocytes tested at the time of surgery. Correlation with the postsurgical clinical course

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960137-2

Prediction of postoperative clinical course by autologous tumor-killing activity in lung cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960137-2

Levamisole as an adjuvant to chemotherapy in extensive bronchogenic carcinoma: a Veterans Administration Lung Cancer Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960137-2

Tumor-derived interleukin-2-dependent lymphocytes in adoptive immunotherapy of lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960137-2

Cancer immunotherapy: current status of treatment with interleukin 2 and lymphokine-activated killer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960137-2

Adjuvant, specific, active immunotherapy for resectable squamous cell lung carcinoma: a 5-year survival analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960137-2

10.1016/S0025-6196(12)60137-2

7 January 2021

Identifiers

DOI

1 reference

24 September 2017

1 reference